Indraprastha Medical Corporation Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 40% at ₹4/Share	18-Sep-2026	18-Sep-2026
DividendsFinal Dividend of 45% at ₹4.5/Share	18-Sep-2025	18-Sep-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
ICICI Prudential Healthcare Fund - Growth	-	9.19 Lac (100%)
Groww BSE Hospitals ETF	29.50 k	31.49 k (6.73%)
Motilal Oswal BSE Healthcare ETF	1.21 k	1.23 k (1.57%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth	567	578 (1.94%)
Motilal Oswal BSE 1000 Index Fund - Regular Plan - Growth	131	130 (0.76%)

Adarsh Nimborkar (SEBI IA)

8 Aug • 10:32 AM · SEBI-Registered Analyst

Indraprastha Medical Corporation Ltd – Company Analysis

INDRAMEDCO

Indraprastha Medical Corporation Ltd operates Indraprastha Apollo Hospital in New Delhi and is part of the Apollo Hospitals Group. The company provides advanced tertiary and quaternary healthcare services across cardiac sciences, oncology, neurosciences, organ transplantation, orthopaedics and other specialties. Its strong clinical capabilities, established brand and presence in the Delhi-NCR healthcare market provide a significant competitive advantage. Financial performance remains healthy, although margins require monitoring. FY26 revenue increased 9.3% to approximately ₹1,483 crore, while net profit rose 14.1% to ₹183.6 crore. Q4 FY26 revenue grew 9.3% year-on-year to ₹364.8 crore, while profit increased modestly to ₹41.7 crore. However, the operating margin declined to 16.6% from 18.4% in the corresponding quarter, indicating some pressure from rising operating costs. Looking ahead, Indraprastha Medical Corporation is well positioned to benefit from rising demand for tertiary healthcare, increasing prevalence of lifestyle diseases, medical tourism and expansion of specialized treatment capacity. The company's association with Apollo provides access to established clinical expertise and brand strength. The latest Q1 FY27 performance was encouraging, with revenue rising 11% and net profit increasing 9% year-on-year, supporting the broader growth outlook. However, investors should monitor margin pressure, employee and operating costs, competition from other hospital chains and the capital required for capacity expansion. Overall, the company represents a fundamentally strong healthcare business with consistent earnings growth and a strong market position, although future returns will depend on sustaining patient volumes and recovering operating margins.

SFP RESEARCH

26 Mar • 6:48 PM · SEBI-Registered Analyst

Indraprastha Medical Corporation Ltd. (Apollo Delhi)

INDRAMEDCO

runs Apollo Hospitals in Delhi region through a JV. It offers tertiary/quaternary care with strong brand in North India. Case‑mix improvement and operating efficiency support earnings. Risks are regulatory caps, intense competition in Delhi‑NCR, and high fixed costs.

THREETREND RESEARCH

15 Dec • 4:55 PM · SEBI-Registered Analyst

FORTIS

Top 10 Healthcare Stocks to Watch: Outperformers of the Last 2 Years!📊 1. Sharma East India Hospitals and Medical Research Ltd. - 218.63% return in 1 year 2. Indraprastha Medical Corporation Ltd. - 115.01% return in 1 year, market cap: ₹2,172.59 Cr 3. Artemis Medicare Services Ltd. - 113.33% return in 1 year 4. Global Health Ltd. - 80.38% return in 1 year, market cap: ₹34,241.4 Cr 5. Dr. Agarwal’s Eye Hospital - 124.17% return in 1 year, market cap: ₹1,501.11 Cr 6. Kovai Medical Center and Hospital - 90.47% return in 1 year, market cap: ₹4,676.87 Cr 7. Apollo Hospitals Enterprise Ltd. - 1-year return: -7.10%, market cap: ₹96,451 Cr 8. Max Healthcare Institute Ltd. - 1-year return: 13.93%, market cap: ₹88,969 Cr 9. Fortis Healthcare Ltd. - 1-year return: 41.22%, market cap: ₹38,167 Cr 10. Krishna Institute of Medical Sciences Ltd. - 1-year return: 33.69%, market cap: ₹17,018 Cr

THREETREND RESEARCH

9 Dec • 9:18 AM · SEBI-Registered Analyst

20 Smallcaps for Research – Low to High PE with Growth Themes Stock-Specific Impact: Research watchlist spanning PE 16-110x with strong order books, EV/defence tailwinds Update Summary Curated list of 20 smallcaps highlighting attractive PE multiples and growth catalysts. Focus on export orders, EV components, defence/rail, EMS, and massive order books. Not buy/sell calls – for long-term research. Key Business Details Low PE Leaders (16-30x) - Ashapura Minechem (PE 16.3): Export orders rising - SKM Egg (PE 19.3) - Banco Products (PE 24.7) - Indraprastha Medical (PE 24.8) - Fiem Industries (PE 26.4): EV lighting - Parag Milk Foods (PE 28.1) Mid PE Growth (31-50x) - Belrise Industries (PE 31.5): Auto ancillary - HBL Engineering (PE 33.9): Defence + Rail - Gravita India (PE 36.5) - CCL Products (PE 37.5): Coffee contracts - Pricol (PE 38.6): EV cockpit systems - Yatharth Hospital (PE 43.4) - Lumax Auto Tech (PE 49.1): Data center pipeline - Jain Resource Recycling (PE 50) High PE Order Book Plays (52x+) - TD Power Systems (PE 52.3): ₹1,468cr OB - Atlanta Electricals (PE ~55): ₹2,070cr OB - Syrma SGS (PE 62.4): EMS + AI infra - KRN Heat Exchanger (PE 82.4): ₹1,000cr backlog - Transrail Lighting (PE ~18): ₹17,800cr OB - Apollo Micro Systems (PE 110): DRDO orders Impact on Company Strong order visibility in defence, rail, EV, EMS. Export tailwinds for minechem/CCL. Healthcare steady growth. Massive OB in electricals/power (Transrail ₹17.8k cr standout). PE spread reflects execution risk vs growth potential. Key Takeaway Gold research list for smallcap learners – low PE exports to high PE order book monsters across EV, defence, EMS, healthcare. Wide PE range offers entry points based on risk appetite and conviction.

GRAVITA

Pradeep Carpenter

3 Nov • 8:58 AM · SEBI-Registered Analyst

Q2 FY25 Earnings Review

🔹 Strong Performers: RR Kabel, BPCL, Bank of Baroda, SBFC Finance, Azad Engineering, Tatva Chintan, Orient Cement, and Indraprastha Medical delivered robust quarterly results. These companies showed strong topline growth, margin expansion, and steady guidance for H2. Banking, energy, and specialty chemical segments stood out with resilient demand and operational efficiency. 🔹 Inline / Mixed Performance: Urban Company, Phoenix Mills, JK Cement, Schaeffler India, Patanjali Foods, Mahindra Holidays, Mahindra Lifespace, Zensar Technologies, and Sanghi Industries reported results broadly in line with expectations. While revenue trends remained stable, margin pressure and cautious outlooks in some sectors led to a mixed overall tone. 🔹 Weak Set: Godrej Consumer (despite strong H2 guidance), CDSL, Tata Chemicals, Balkrishna Industries, NOCIL, GHCL, and Spandana Sphoorthy underperformed. Margin contraction, weak volume growth, and inventory adjustments weighed on results, especially across chemicals and auto ancillary names.

BPCL

BANKINDIA

ICDSLTD

Stock Reader

3 Nov • 7:37 AM · SEBI-Registered Analyst

Indraprastha Medical Corporation Ltd (Apollo Hospitals Delhi) – Quiet Strength, Consistent Growth & Expanding Horizons

INDRAMEDCO

Indraprastha Medical Corporation, the flagship operator of Apollo Hospitals in Delhi and Noida, continues to build momentum as one of India’s most reliable and fundamentally strong healthcare plays. My outlook on the stock is bullish, rooted in its consistent financial performance, improving margins, and strategic focus on high-value medical services. The company has been steadily transforming from a regional healthcare provider into a technology-driven, multi-specialty medical hub known for clinical excellence and operational discipline. In its latest quarterly results, Indraprastha Medical reported a healthy uptick in both top-line and bottom-line performance, supported by an increase in patient inflows, strong occupancy rates, and higher contribution from complex procedures such as oncology, cardiology, and organ transplants. Revenue grew by double digits year-on-year, while net profit surged meaningfully, reflecting improved efficiency, better case mix, and prudent cost management. The hospital’s focus on specialized care and adoption of advanced medical technologies have significantly enhanced both patient outcomes and profitability. One of the standout positives is the company’s debt-free balance sheet and strong cash generation, which allows continuous reinvestment into infrastructure and digital healthcare initiatives without leverage pressure. Indraprastha Medical has also been expanding its outreach through telemedicine and outpatient partnerships, catering to the rising demand for quality healthcare in northern India. With the healthcare sector expected to benefit from rising insurance penetration, medical tourism, and lifestyle-driven health awareness, the company is strategically placed to capture long-term growth opportunities. Operationally, the hospital has maintained high occupancy levels above 70%, while its continuous focus on clinical excellence keeps it among the preferred tertiary care centers in the NCR region.

Indraprastha Medical Corporation Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Indraprastha Medical Corporation Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Indraprastha Medical Corporation Ltd.?

What is the market cap of Indraprastha Medical Corporation Ltd.?

Should I buy Indraprastha Medical Corporation Ltd. stock now?

What is the 52 week high and low of Indraprastha Medical Corporation Ltd.?

Is the Indraprastha Medical Corporation Ltd. stock good to buy?

Is Indraprastha Medical Corporation Ltd. a good buy for the long term?

Is Indraprastha Medical Corporation Ltd. overvalued or undervalued?

What is the PE and PB ratio of Indraprastha Medical Corporation Ltd.?